rupiya.io
⠋Loading...
0%
❯ Processing cash flow data...
Zydus is a leading Indian company in the Pharmaceuticals space, listed on the NSE. The company is a key player in the Pharma — Formulations segment with a strong market position and diversified operations.
Zydus Lifesciences Ltd makes money through Core Business, Other Segments, Exports in Pharma — Formulations. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Metric | 1 Year | 3 Years | 5 Years | 10 Years |
|---|---|---|---|---|
| Sales | — | — | — | — |
| Profit | — | — | — | — |
| Stock Price | — | — | — | — |
| ROE | — | — | — | — |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹7,224 Cr | ₹8,651 Cr | ₹9,427 Cr |
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,257 Cr | ₹5,011 Cr | ₹5,140 Cr | ₹4,369 Cr | ||||||||
| Expenses | ₹3,301 Cr | ₹3,755 Cr | ₹3,634 Cr | ₹3,223 Cr | ||||||||
| Operating Profit | ₹956 Cr | ₹1,256 Cr | ₹1,505 Cr | ₹1,146 Cr |
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹102 Cr | ₹102 Cr | ₹102 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,337 Cr | ₹4,149 Cr | ₹5,597 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹903 Cr | ₹-438 Cr | ₹-529 Cr | — |
| Mar 2016 | ₹994 Cr | ₹-465 Cr | ₹-351 Cr | — |
| Mar 2017 | ₹1,894 Cr | ₹-860 Cr | ₹-935 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 |
| Ratio | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 15.1% | 14.0% | 14.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| ROCE % | 16.6% | 15.5% | 15.6% | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt/Equity | 0.5 | 0.4 | 0.5 | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 10.4 | 9.7 | 12.2 | — | — | — | — | — | — | — | — | — |
| Year | Type | Amount (₹) |
|---|---|---|
| FY24 | Final | ₹19.89 |
| FY23 | Final | ₹4.41 |
| FY22 | Final | ₹19.94 |
| FY21 | Interim | |
| FY20 | Final | |
| FY19 | Interim |
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.
Deep-dive analysis of Zydus's competitive moat, management quality, and growth runway available with Premium.
Premium| Expenses | ₹6,021 Cr | ₹6,896 Cr | ₹7,095 Cr |
| Operating Profit | ₹1,203 Cr | ₹1,756 Cr | ₹2,332 Cr |
| OPM % | 17.0% | 20.0% | 25.0% |
| Other Income | ₹30 Cr | ₹45 Cr | ₹112 Cr |
| Depreciation | ₹201 Cr | ₹287 Cr | ₹292 Cr |
| Interest | ₹90 Cr | ₹68 Cr | ₹53 Cr |
| Profit Before Tax | ₹942 Cr | ₹1,446 Cr | ₹2,099 Cr |
| Tax | ₹942 Cr | ₹1,446 Cr | ₹2,099 Cr |
| Net Profit | ₹836 Cr | ₹1,188 Cr | ₹1,964 Cr |
| EPS (₹) | 7.9 | 11.2 | 18.9 |
| Dividend Payout % | 23% | 21% | 17% |
Register free to see 9 more years.
| OPM % | 22.0% | 25.0% | 29.0% | 26.0% |
| Depreciation | ₹182 Cr | ₹179 Cr | ₹180 Cr | ₹184 Cr |
| Interest | ₹33 Cr | ₹28 Cr | ₹18 Cr | ₹9 Cr |
| Net Profit | ₹631 Cr | ₹358 Cr | ₹1,134 Cr | ₹803 Cr |
| EPS (₹) | 6.2 | 2.9 | 10.7 | 7.9 |
Register free to see 8 more quarters.
| Borrowings | ₹2,700 Cr | ₹2,651 Cr | ₹2,442 Cr |
| Other Liabilities | ₹1,847 Cr | ₹2,144 Cr | ₹2,208 Cr |
| Total Liabilities | ₹7,986 Cr | ₹9,047 Cr | ₹10,350 Cr |
| Assets |
| Fixed Assets | ₹3,124 Cr | ₹3,352 Cr | ₹3,748 Cr |
| Investments | ₹87 Cr | ₹154 Cr | ₹416 Cr |
| Receivables | — | — | — |
| Inventory | — | — | — |
| Cash & Equivalents | — | — | — |
| Other Assets | ₹3,885 Cr | ₹4,743 Cr | ₹5,235 Cr |
| Total Assets | ₹7,986 Cr | ₹9,047 Cr | ₹10,350 Cr |
Register free to see 9 more years.
| Mar 2022 |
| Mar 2023 |
| Mar 2024 |
| Mar 2025 |
Register free to see 9 more years.
| — |
| — |
| — |
| Current Ratio | 1.7 | 1.6 | 1.4 | — | — | — | — | — | — | — | — | — | — | — | — |
| Quick Ratio | 1.3 | 1.2 | 1.3 | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | 15.3% | 13.5% | 14.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| NPM % | 9.2% | 8.1% | 8.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 15.3 | 12.1 | 15.7 | — | — | — | — | — | — | — | — | — | — | — | — |
| PEG Ratio | 1.9 | 1.4 | 1.6 | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Turnover | 0.7 | 1.2 | 1.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 7.3 | 5.9 | 10.8 | — | — | — | — | — | — | — | — | — | — | — | — |
Register free to see 12 more years of ratio trends.